1. Home
  2. RGP vs MOLN Comparison

RGP vs MOLN Comparison

Compare RGP & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Resources Connection Inc.

RGP

Resources Connection Inc.

HOLD

Current Price

$4.49

Market Cap

138.0M

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

HOLD

Current Price

$3.80

Market Cap

144.0M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
RGP
MOLN
Founded
1996
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Business Services
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
138.0M
144.0M
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
RGP
MOLN
Price
$4.49
$3.80
Analyst Decision
Strong Buy
Buy
Analyst Count
1
2
Target Price
$7.00
$8.38
AVG Volume (30 Days)
259.7K
2.2K
Earning Date
04-08-2026
05-12-2026
Dividend Yield
6.85%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$551,331,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$374.07
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.06
$3.41
52 Week High
$6.07
$5.36

Technical Indicators

Market Signals
Indicator
RGP
MOLN
Relative Strength Index (RSI) 64.72 45.28
Support Level $4.22 $3.52
Resistance Level $4.52 $4.51
Average True Range (ATR) 0.18 0.13
MACD -0.00 -0.03
Stochastic Oscillator 82.28 38.37

Price Performance

Historical Comparison
RGP
MOLN

About RGP Resources Connection Inc.

Resources Connection Inc provides consulting and business initiative support services predominantly through its operative subsidiary, Resources Global Professionals. It has two segments RGP ( Resources Global Professionals.) and Sitrick. The RGP segment is focused on delivering consulting services catering to its client's operational needs and change initiatives utilizing a combination of bench and on-demand, talent. The Sitrick segment provides corporate, financial, transactional, and crisis communication and management services. The company generates a majority of its revenue from the RGP segment. Geographically, it derives its key revenue from North America and the rest from Europe and the Asia Pacific region.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: